This inventor holds 1 USPTO granted patent and 4 published patent applications, plus 2 CIPO patents and 1 EPO patent. Top assignee: Wyeth. Active years: 2012.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2012
Title: The Innovative Contributions of Andrew Louis Strahs
Introduction
Andrew Louis Strahs, an accomplished inventor based in Maynard, MA, has made significant strides in the field of medical research with his innovative ideas and inventions. His work focuses particularly on the application of protein expression in tumor identification, showcasing the intersection of biotechnology and pharmaceutical development.
Latest Patents
Strahs holds a notable patent titled "Cut-point in PTEN protein expression that accurately identifies tumors and is predictive of drug response to a pan-ErbB inhibitor." This invention presents a quantitative measurement of PTEN protein expression, which effectively identifies tumors with two inactivated alleles of the PTEN gene. The patent outlines a method where patients exhibiting a normalized PTEN score of PTEN null can be treated with a pan-ErbB tyrosine kinase inhibitor. The innovation lies in comparing the tumor PTEN optical density (OD) expression value with non-malignant PTEN OD expression value, providing a reliable tool for assessing drug response.
Career Highlights
Andrew’s career has been marked by his role at Wyeth, where he has contributed to pivotal advancements in drug development and cancer research. His expertise in evaluating protein expression has played a crucial role in optimizing treatment protocols, ultimately aiming to enhance patient outcomes.
Collaborations
Throughout his career, Strahs has collaborated with notable colleagues such as Christina Marie Coughlin and Jay Marshall Feingold. Together, they have fostered a collaborative environment where innovation thrives, leading to groundbreaking discoveries in the realm of cancer treatment.
Conclusion
Andrew Louis Strahs stands out as a vital contributor to the field of medical research. His patent on PTEN protein expression exemplifies how innovative thought can translate into practical applications that may significantly impact patient care. As he continues his work at Wyeth, the potential for further advancements remains high, solidifying his status as an influential inventor in the scientific community.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile